Prime Medicine
PRME
3.90
+0.40
+11.43%
Prime Medicine
US · PRME
#3501 by market cap
Listed 2022
3.90
+0.40
+11.43%
Live - 5344 symbols - heartbeat 552s ago
· 2026-10-08 09:09
Pre-market
3.85
-1.30%
After-hours
3.88
-0.42%
Overnight
3.94
+1.03%
- Market cap
- 707.37M
- P/E (TTM)i
- -3.71
- P/Bi
- 17.81
- EPSi
- -1.35
- Div yieldi
- 0.00%
- 52W posi
- 31%
Reader sentiment
Are you bullish or bearish on PRME?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 11.1 percentage points.
Institutional ownership
- Held by institutions
- 76.11% -11.13pp
- Institutions
- 226 -5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund32.83%
VC/PE Fund22.40%
Individual/Insider14.52%
Hedge Fund10.45%
Public Company8.96%
Private Company0.72%
Family Office/Trust0.46%
Government Pension Fund0.16%
Insurance Company0.14%
Other9.37%
Top holders as of 2026-03-31
David Liu
11.38% · 20.24M sh
GV Management Company, LLC
9.31% · 16.56M sh
Arch Venture Partners, L.P.
6.89% · 12.26M sh
Bristol-Myers Squibb Company
6.19% · 11.01M sh
BlackRock
5.40% · 9.60M sh
ARK Investment Management LLC
4.69% · 8.35M sh
State Street Global Advisors
4.26% · 7.58M sh
Newpath Management, L.P.
3.43% · 6.11M sh
T. Rowe Price Group, Inc.
3.04% · 5.40M sh
Vanguard Capital Management, LLC
2.97% · 5.29M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 40 buys · 10 sells
| Name | Role | Stake |
|---|---|---|
| David Liu | Co-Founder & Chair of Scientific Advisory Board | 11.38% |
| Keith Gottesdiener | Chief Executive Officer | 2.45% |
| Jeremy Duffield | Chief Scientific Officer | 0.54% |
| Allan Reine | Chief Financial Officer | 0.07% |
| Ann Lee | Chief Technology Officer | 0.06% |
| Richard Brudnick | Chief Business Officer | 0.01% |
| Robert Taylor Nelsen | Independent Director | 0.01% |
| Michael Kelly | Independent Director | -- |
| Kaye Foster-Cheek | Independent Director | -- |
| David Schenkein | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-04 | Robert Taylor Nelsen | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Michael Kelly | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Kaye Foster-Cheek | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | David Schenkein | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Jeffrey Marrazzo | Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Wendy Chung | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Thomas Cahill | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-02-25 | Allan Reine | Chief Financial Officer | Other Derivative Acquisition | +1,300,000 | $4.38 |
| 2026-02-22 | Ann Lee | Chief Technology Officer | Other Derivative Acquisition | +375,000 | $3.34 |
| 2026-02-22 | Carman Alenson | Chief Accounting Officer & Interim CFO | Other Derivative Acquisition | +140,000 | $3.34 |
| 2025-07-31 | Robert Taylor Nelsen | Independent Director | Derivative Sale to Issuer | -84,062 | -- |
| 2025-07-31 | Robert Taylor Nelsen | Independent Director | Other Derivative Acquisition | +84,062 | $4.04 |
| 2025-07-31 | Michael Kelly | Independent Director | Derivative Sale to Issuer | -106,578 | -- |
| 2025-07-31 | Michael Kelly | Independent Director | Other Derivative Acquisition | +106,578 | $4.04 |
| 2025-07-31 | Kaye Foster-Cheek | Independent Director | Derivative Sale to Issuer | -106,578 | -- |
| 2025-07-31 | Kaye Foster-Cheek | Independent Director | Other Derivative Acquisition | +106,578 | $4.04 |
| 2025-07-31 | David Schenkein | Independent Director | Derivative Sale to Issuer | -84,062 | -- |
| 2025-07-31 | David Schenkein | Independent Director | Other Derivative Acquisition | +84,062 | $4.04 |
| 2025-07-31 | Ann Lee | Chief Technology Officer | Derivative Sale to Issuer | -361,990 | -- |
| 2025-07-31 | Ann Lee | Chief Technology Officer | Other Derivative Acquisition | +361,990 | $4.04 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:09:33 · For reference only, not investment advice and not tailored to your situation.